Provider review
Collective Review: It Cites the Trials Correctly, Then Builds the Calculator on a Bigger Number
Collective quotes the semaglutide and tirzepatide trial results correctly — about 15% and about 20–22% — and, unusually, keeps the phrase "when combined with diet and lifestyle changes" that most sellers drop. Then its homepage slider, the thing a buyer actually touches, computes a personal target from 23%: a figure above the trial ceiling the same page just quoted, attributed to an unnamed real-world study of a compounded preparation that has never been through a randomized trial.
Quotes the trials correctly in its FAQ, then runs its weight-loss calculator on a bigger, unsourced number for the compounded version.
Worth trusting if
- You want a seller whose quoted trial figures are actually the trial figures
- You value a tool that tells you the result may not be appropriate for your body size
- You read the FAQ rather than the slider
Be skeptical if
- You are planning around the calculator's projection, which uses a figure above the trial results
- You want to know which pharmacy compounds your prescription, or who prescribes it, because neither is named
- You are budgeting from the headline monthly price, which excludes a mandatory annual membership
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.collective.org. A link is not a recommendation to take anything.
Provenance
What Collective actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide — Advertised at $59 a month, which does not include the mandatory $199 annual membership.
- Compounded tirzepatide — The same $59 monthly framing applies, again before the $199 annual membership.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Collective.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Collective’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Semaglutide is a GLP-1 medication that helps reduce hunger, increase feelings of fullness, and support weight loss. In clinical studies, participants lost an average of about 15% of their body weight when combined with diet and lifestyle changes.”
Read on the Collective site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in adults with obesity or overweight and a weight-related condition; mean weight reduction of 14.9% on semaglutide 2.4mg alongside lifestyle intervention.
This is what an accurate citation looks like, and it is rare enough here to be worth naming. STEP 1 reported 14.9%; "about 15%" is that number, rounded honestly rather than up to the nearest impressive one. The mechanism clause is right. And the sentence keeps "when combined with diet and lifestyle changes", which is the condition every participant in that trial was under and the clause most sellers quietly delete. The one thing left unsaid is that STEP 1 tested the branded product, while what Collective dispenses is compounded and has no trial of its own.1
Compounded tirzepatideTirzepatide · Compounded (503A)Claim reaches past the trials
“See what each medication achieved in real-world studies. Average weight loss seen in real-world studies 46 lbs. Potential weight after treatment 154 lbs (Based on real-world results of 23% body weight). In a real-world study, where most patients used compounded tirzepatide, people averaged about 23% of body weight over 12 months.”
Read on the Collective site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks, adults with obesity or overweight without diabetes. Mean weight reduction of 20.9% at 15mg in the efficacy estimand, around 22.5% in the on-treatment analysis. The trial used branded tirzepatide; no randomized trial of a compounded preparation has been published.
The number the calculator runs on is larger than the number the same site attributes to the trials. Collective's own FAQ says clinical studies produced "about 20–22%", which is right. Its slider computes from 23%, sourced to "a real-world study, where most patients used compounded tirzepatide" — unnamed, and describing a preparation that has never been through a randomized trial. So the highest figure on the site is the one attached to the least-tested version of the drug, and it is the one wired into the tool that turns a buyer's current weight into a target. Two things stop this being worse than it is, and they are worth stating: the slider says plainly "these are averages, not a prediction of your results", and it adds that the amount "may not be appropriate for your body size. A doctor will decide what is right for you." That is better hedging than anything comparable in this batch. The problem is the provenance of the 23%, not an absence of caveats.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named, and no clinician, medical director or advisory name is published anywhere on the marketing site. The operating entity is Health For Everyone Inc., trading as CollectiveOS. One gap worth flagging for anyone reading the legal pages: the Terms and Privacy Policy describe the platform as covering "GLP-1s, peptides, and related products", and no peptide product is published for sale anywhere on the site — so the contract is written wider than the catalog.
Read on the Collective site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. What Collective does better than most of this market is cite its evidence accurately: both of the effect sizes in its FAQ match the published trials, and both retain the qualifier that the results came alongside diet and lifestyle changes. The gap is one level down, in the interactive slider — it invokes "real-world studies" of compounded product, gives a figure larger than the trials it quotes elsewhere, and names no study a reader could look up.
Read on the Collective site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
No per-state list is published on the marketing site.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The entity is Health For Everyone Inc., doing business as CollectiveOS.
Read on the Collective site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its semaglutide figure — about 15% — matches STEP 1's reported 14.9%, rounded honestly rather than upward.
- Its tirzepatide figure — about 20–22% — spans SURMOUNT-1's efficacy and on-treatment results, and giving it as a range is the accurate way to state it.
- Both figures keep the phrase "when combined with diet and lifestyle changes", the trial condition that most sellers delete.
Show 4 more
- Its slider says plainly that these are averages and not a prediction of an individual's results.
- It adds that the projected loss may not be appropriate for the reader's body size and that a doctor will decide — better hedging than anything comparable in this batch.
- Prices are visible before any intake or account.
- No FDA warning letter against Health For Everyone Inc. or Collective.
- Its weight-loss calculator computes from 23%, a figure higher than the 20–22% the same page attributes to the clinical trials.
- That 23% is sourced to an unnamed "real-world study" of compounded tirzepatide, a preparation with no published randomized trial.
- So the largest number on the site is attached to the least-tested version of the drug, and it is the one wired into the interactive tool.
Show 5 more
- The headline monthly price omits a mandatory annual membership disclosed only in a card panel, a small disclaimer and the FAQ.
- The homepage says "Save up to 84%" while the signup flow says "Up to 86% lower pricing".
- No pharmacy is named.
- No clinician, medical director or advisory name is published anywhere.
- The Terms describe a platform covering peptides, and no peptide is sold on the site.
Verdict
The bottom line
Read Collective's FAQ and you get the trial results, correctly stated, with the lifestyle qualifier intact — which is more than most of this market manages. Use its slider and you get a projection built on 23%, a number above the trials it just quoted, credited to an unnamed real-world study of a compounded product that has never been randomized. The caveats around that slider are genuinely good. The number inside it is the one to discount.
Opens www.collective.org. A link is not a recommendation to take anything.
Start with what is right
Two claims from Collective's homepage FAQ, read live:
Semaglutide — "In clinical studies, participants lost an average of about 15% of their body weight when combined with diet and lifestyle changes."
Tirzepatide — "In clinical studies, participants lost an average of about 20–22% of their body weight when combined with diet and lifestyle changes."
Both are accurate. STEP 1 reported 14.9%. 1 SURMOUNT-1 reported 20.9% in its efficacy estimand and around 22.5% on treatment, so a 20–22% range is the honest way to give it. 2
And both keep the clause that everyone else drops. Every participant producing those numbers was also on a lifestyle intervention. Sellers delete that phrase constantly, because it implies the drug is not the whole story. Collective kept it. Twice.
Full analysis — 3 more sectionsThen look at what the calculator runs on · The caveats deserve credit · What is not named
Then look at what the calculator runs on
The homepage carries an interactive slider, headed:
"See what each medication achieved in real-world studies."
Set it to 200 lbs and it returns:
Average weight loss seen in real-world studies 46 lbs
Potential weight after treatment 154 lbs
( Based on real-world results of 23% body weight )
Twenty-three percent. Above the 20–22% the same page attributes to the clinical trials, two scroll-lengths away.
The source, given underneath:
"In a real-world study, where most patients used compounded tirzepatide, people averaged about 23% of body weight over 12 months."
No study is named. And compounded tirzepatide has no published randomized trial at all — the SURMOUNT program tested the branded product.
So the largest figure on the site belongs to the least-tested version of the drug, and it is the one wired into the tool a buyer actually touches.
The caveats deserve credit
It would be easy to stop there, and it would be unfair. Beside that slider, on the same screen:
"These are averages, not a prediction of your results. Individual outcomes vary with health, lifestyle…"
"This amount of weight loss may not be appropriate for your body size. A doctor will decide what is right for you."
That second sentence is better than anything comparable we found in this sweep. Most weight-loss calculators in this market hand you a number and stop.
The criticism here is narrow and specific: it is about where the 23% came from, not about a failure to hedge. Collective hedged. It just hedged around a figure it cannot source, for a product nobody has tested in a trial.
What is not named
No pharmacy. No clinician. No medical director.
And a small oddity in the legal pages: the Terms and Privacy Policy describe a platform covering "GLP-1s, peptides, and related products". No peptide is sold anywhere on the site. The contract is written wider than the catalog.
Questions
Frequently asked questions
Are Collective's weight-loss figures accurate?
The ones in its FAQ are. "About 15%" for semaglutide matches STEP 1's 14.9%, and "about 20–22%" for tirzepatide spans SURMOUNT-1's efficacy and on-treatment results. Both also keep the phrase "when combined with diet and lifestyle changes", which is the trial condition and the clause most sellers drop.
Then why does the calculator say 23%?
Because it uses a different source. The slider credits "a real-world study, where most patients used compounded tirzepatide", names no study, and produces a figure above the trial results quoted elsewhere on the same page. Compounded tirzepatide has no published randomized trial, so there is nothing to check that number against.
Should I plan around the projection it gives me?
No, and to its credit the site says so. The slider states that these are averages rather than a prediction, and adds that the amount may not be appropriate for your body size and that a doctor will decide. Take those caveats seriously and discount the 23% they are attached to.
What will I actually pay?
More than the headline. The monthly price advertised in the H1 does not include a mandatory annual membership, which appears only in a card panel, a small disclaimer and the FAQ.
Does Collective sell peptides?
No. Its Terms and Privacy Policy describe a platform covering "GLP-1s, peptides, and related products", and no peptide product is published for sale anywhere on the site. The contract is written wider than the catalog.
Who compounds and who prescribes?
The site does not say. No pharmacy is named, and no clinician, medical director or advisory name is published anywhere on the marketing site.
Glossary
Key terms
Show definitions
- Real-world study
- An observational look at what happened to patients in ordinary care, rather than a randomized trial. It can be informative and it cannot control for who chose the treatment, so its numbers are not interchangeable with trial results.
- Efficacy estimand
- The pre-specified analysis covering everyone randomized, including those who stopped early. The on-treatment analysis counts only those still taking the drug and usually yields a larger number.
Compare
Others selling what Collective sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Collective's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 participants, mean weight reduction 14.9% alongside lifestyle intervention. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 participants, 20.9% in the efficacy estimand and around 22.5% on treatment, using branded tirzepatide. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.